Spark, Pfizer report progress on gene therapy for hemophilia

Spark Therapeutcis and Pfizer have cleared a key hurdle in their effort to develop a gene therapy treatment for patient with hemophilia B. On Tuesday, the companies said all 15 hemophilia B patients in Philadelphia-based Spark’s ongoing phase-I/II clinical trial of its investigational gene therapy SPK-9001 had discontinued routine infusions of factor IX concentrates – and none of the 15 participants experienced serious adverse ev ents. Hemophilia B is a rare, genetic bleeding disorder found…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news